Equities

Nectar Lifesciences Ltd

NECLIFE:NSI

Nectar Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)31.45
  • Today's Change0.70 / 2.28%
  • Shares traded230.01k
  • 1 Year change+77.68%
  • Beta1.1910
Data delayed at least 15 minutes, as of Jun 07 2024 11:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.

  • Revenue in INR (TTM)16.86bn
  • Net income in INR49.95m
  • Incorporated1995
  • Employees1.59k
  • Location
    Nectar Lifesciences LtdSco 38-39,, Sector 9-DCHANDIGARH 160009IndiaIND
  • Phone+91 1 723047777
  • Fax+91 1 723047755
  • Websitehttps://www.neclife.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Wanbury Ltd5.76bn559.56m4.69bn1.58k8.3716.776.790.81417.0917.09175.718.531.7810.437.27--17.3011.6399.14--47.4343.799.727.620.57571.950.8065--15.218.02638.26--29.87--
ZIM Laboratories Ltd3.67bn172.46m4.97bn525.0028.872.0814.991.353.543.5475.3449.000.93212.543.76--4.383.886.666.5453.3448.304.693.970.91823.670.3131---7.801.84-29.422.3729.41--
Kilitch Drugs (India) Ltd1.54bn146.02m5.23bn153.0035.442.9630.883.399.179.1797.14109.620.671830.802.63--5.913.388.274.7639.8136.088.796.172.213.510.153--10.5813.3539.7530.69-19.45--
Valiant Laboratories Ltd1.82bn3.40m5.89bn--322.622.49257.273.230.420.4249.5554.51----------------7.58--0.187--7.41-133.110.2446---45.48---98.83------
IND Swift Laboratories Ltd12.81bn3.07bn5.91bn1.50k1.920.63471.640.461551.9951.99216.90157.640.8573.453.80--20.585.0025.676.1339.4742.8224.028.522.941.700.0175--6.1011.10784.4470.8223.60--
Medicamen Biotech Ltd1.79bn109.31m5.91bn388.0057.332.9535.653.308.118.11135.05157.680.62581.772.98--3.315.894.758.4948.3639.065.299.581.103.440.13328.4627.297.90-26.36-1.89-16.710.00
Albert David Ltd3.62bn754.20m6.11bn1.27k8.101.607.431.69132.16132.16635.16671.050.78682.6712.15--16.3710.0020.8513.1565.3061.0320.8111.873.31124.700.008612.896.122.72108.4933.5940.8713.90
Nectar Lifesciences Ltd16.86bn49.95m6.65bn1.59k128.910.621910.120.39450.230.2379.1647.680.76971.745.12--0.228-0.29560.3969-0.54128.6818.390.2963-0.40520.59071.060.3728--10.63-9.54120.65-36.29-5.06--
Sakar Healthcare Ltd1.53bn116.71m6.68bn297.0055.122.5522.474.355.575.5773.21120.610.4233.887.13--3.225.263.816.2845.4344.137.6010.120.7432.680.2322--14.9917.58-8.5311.7619.05--
Panacea Biotec Ltd5.59bn-9.40m7.62bn1.09k--0.905321.651.36-0.16-0.1691.52137.480.44521.219.52---0.119410.26-0.159716.5358.8552.88-0.268324.870.9948-15.860.0244--21.574.1396.48--74.65--
Bajaj Healthcare Ltd4.73bn-143.27m7.91bn1.06k--2.8459.491.67-5.18-30.36171.62100.860.56811.442.32---1.726.97-3.5112.7346.1830.16-3.037.200.80961.640.54465.38-29.695.04-133.30--15.08--
Jagsonpal Pharmaceuticals Ltd2.09bn224.63m8.63bn940.0038.524.6035.764.138.478.4778.3170.881.015.2713.12--10.9010.9512.3013.2955.0058.1710.769.219.6326.290.045543.81-11.834.58-15.9425.50-35.6982.06
Data as of Jun 07 2024. Currency figures normalised to Nectar Lifesciences Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

1.07%Per cent of shares held by top holders
HolderShares% Held
Kotak Mahindra (UK) Ltd.as of 30 Jun 20232.39m1.06%
American Century Investment Management, Inc.as of 09 May 20242.21k0.00%
Data from 26 Jul 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.